| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3275269 | Médecine des Maladies Métaboliques | 2009 | 8 Pages |
Abstract
The kidney has an important role in glucose metabolism and regulation. The renal sodium glucose co-transporter 2 (SGLT2) has a key role in the active transport of glucose by determining renal glucose reabsorption, thus representing a potential target for pharmacological diabetes treatment. Effects of SGLT2 inhibitors in various animal models, as well as currently available phase 2 clinical results with oral selective SGLT2 inhibitors in type 2 diabetic patients are presented and discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
F. Bonnet, J.-P. Sauvanet,